We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application

This study has been withdrawn prior to enrollment.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00466570
First Posted: April 27, 2007
Last Update Posted: June 13, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Christopher Ta, Stanford University
  Purpose
Topical ophthalmic antibiotics are common prescribed just prior to eye surgery to lower the risk of infection. Previous studies have suggested that antibiotics containing a preservative (Zymar) kill bacteria much quicker than those without a preservative (Vigamox). The purpose of this research is to compare how quickly to the two commonly prescribed antibiotics eliminate bacteria from the eye surface.

Condition Intervention
Conjunctical Flora Drug: gatifloxacin, moxifloxacin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single
Primary Purpose: Prevention
Official Title: Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour

Resource links provided by NLM:


Further study details as provided by Christopher Ta, Stanford University:

Primary Outcome Measures:
  • Antibiotic killing of conjunctival bacterial flora 1 hour after application

Enrollment: 0
Study Start Date: April 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age- older than 50 years of age
  • Diagnosis- Cataract or had cataract surgery

Exclusion Criteria:

  • Systemic or topical antibiotic treatment within 30 days
  • Use of systemic or topical steroids
  • Active ocular infection
  • Ocular surgery in the past 6 months
  • Allergy to fluoroquinolones
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00466570


Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Christopher Ta, MD Stanford University
  More Information

Publications:
Responsible Party: Christopher Ta, Principal Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT00466570     History of Changes
Other Study ID Numbers: 8924
First Submitted: April 25, 2007
First Posted: April 27, 2007
Last Update Posted: June 13, 2013
Last Verified: June 2013

Additional relevant MeSH terms:
Moxifloxacin
Fluoroquinolones
Gatifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors